NasdaqGS - Nasdaq Real Time Price USD

Pharvaris N.V. (PHVS)

Compare
20.82 +0.26 (+1.26%)
At close: October 15 at 4:00 PM EDT
Loading Chart for PHVS
DELL
  • Previous Close 20.56
  • Open 20.62
  • Bid 20.39 x 100
  • Ask 21.12 x 100
  • Day's Range 20.50 - 21.14
  • 52 Week Range 15.00 - 33.00
  • Volume 55,674
  • Avg. Volume 91,340
  • Market Cap (intraday) 1.124B
  • Beta (5Y Monthly) -3.10
  • PE Ratio (TTM) --
  • EPS (TTM) -2.85
  • Earnings Date Aug 14, 2024
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 34.53

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial. The company operates in the Netherlands, Switzerland, and the United States. Pharvaris N.V. was incorporated in 2015 and is based in Leiden, the Netherlands.

pharvaris.com

83

Full Time Employees

December 31

Fiscal Year Ends

Recent News: PHVS

View More

Performance Overview: PHVS

Trailing total returns as of 10/15/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

PHVS
25.78%
S&P 500
21.92%

1-Year Return

PHVS
10.16%
S&P 500
34.37%

3-Year Return

PHVS
31.55%
S&P 500
31.03%

5-Year Return

PHVS
16.72%
S&P 500
49.61%

Compare To: PHVS

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: PHVS

View More

Valuation Measures

Annual
As of 10/15/2024
  • Market Cap

    1.11B

  • Enterprise Value

    731.34M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    --

  • Price/Book (mrq)

    3.08

  • Enterprise Value/Revenue

    --

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -26.79%

  • Return on Equity (ttm)

    -45.05%

  • Revenue (ttm)

    --

  • Net Income Avi to Common (ttm)

    -114.1M

  • Diluted EPS (ttm)

    -2.85

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    343.57M

  • Total Debt/Equity (mrq)

    0.04%

  • Levered Free Cash Flow (ttm)

    -55.19M

Research Analysis: PHVS

View More

Earnings Per Share

Consensus EPS
 

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell
 

Analyst Price Targets

13.96 Low
34.53 Average
20.82 Current
49.86 High
 

Company Insights: PHVS

People Also Watch